AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (ABBV) announced that its Allergan Aesthetics business will hold BOTOX Cosmetic Day on November 18, 2026, with offers for Allē members.
Starting at 9 a.m. PT, members who buy a $50 gift card will receive another $50 gift card free, while supplies last. Cards are redeemable for future BOTOX Cosmetic treatments at participating Allē providers. A November referral offer gives members and their referred friends $50 off qualifying products or treatments. The friend must register and receive treatment November 1–30; each member is limited to one referral offer.
Allergan Aesthetics, an AbbVie (ABBV) company, named 20 women entrepreneurs as 2026 grant recipients of its BOTOX Cosmetic-funded Confidence Collective. Each recipient received $20,000 to support her business goals.
In the program's fourth year, 250 women entrepreneurs received coaching, business tools and guidance before a panel selected the grant recipients. Since 2023, the initiative has provided more than 500 women entrepreneurs with business-building resources and community connections and awarded more than $1.5 million in grants.
AbbVie (ABBV) submitted a U.S. FDA biologics license application for etentamig to treat adults with relapsed or refractory multiple myeloma.
The application is supported by the Phase 3 CERVINO study, which compared etentamig with investigator-selected standard therapies in patients exposed to three treatment classes after at least two prior treatment lines. Etentamig achieved statistically significant improvements in both primary measures: overall response was 74.0% versus 45.7%, and progression-free survival, the time without disease worsening, showed a 60% risk reduction. Treatment-emergent adverse events led to discontinuation in 3.6% versus 14%. Grade 3/4 infections occurred in 27.7% versus 19.2%, while grade 5 infections occurred in 1.5% versus 3.1%. Among patients receiving a single step-up dose, cytokine release syndrome occurred in 28.3%, with no grade 3 or higher events reported.
AbbVie (ABBV) is marking eight years of its Allergan Aesthetics business partnering with Girls Inc. on STEM education. A planned San Antonio workshop will bring together 20 participants and alumnae for career exploration and a private panel with local women healthcare providers.
SkinSpirit will support the partnership for a third consecutive year. From November 1–15, 2026, clients will be invited to donate directly to Girls Inc. to support science, technology, engineering and mathematics programming, mentorship and career exploration across the United States and Canada.
AbbVie (ABBV) received FDA approval for subcutaneous SKYRIZI induction treatment in adults with moderately to severely active Crohn's disease. Patients can now start treatment at home using an on-body injector. Induction dosing is 720 mg at weeks 0, 2, 4 and 8, followed by maintenance starting at week 12 and continuing every eight weeks.
In the Phase 3 AFFIRM trial, week-12 clinical remission was 56% with subcutaneous SKYRIZI versus 30% with placebo; endoscopic response, a measure of improvement seen during intestinal examination, was 43% versus 15%. Among patients without prior advanced therapy failure, these rates were 74% versus 27% and 60% versus 15%, respectively. No new safety risks were observed. The FDA also approved label changes across all approved indications allowing clinicians to determine whether pretreatment tuberculosis testing is needed using clinical judgment.
AbbVie (ABBV) reported that investigational lutikizumab met the primary endpoint in its Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At Week 16, 31.4% versus 23.4% on placebo achieved HiSCR75: at least a 75% reduction in abscesses and inflammatory nodules, without increased abscesses or draining fistulas (p≤0.001).
The trial enrolled 1,400 adults and adolescents and met 8 ranked secondary endpoints. At Week 8, 26.2% versus 15.0% achieved at least a 3-point skin-pain reduction. Flares occurred in 18.4% versus 28.1% over 16 weeks. Overall adverse-event rates were 53.4% versus 53.7%; serious-event rates were 3.0% versus 2.9%. No new safety concerns were identified. AbbVie expects extension data in 2027 to support regulatory submissions in the second half of that year.
AbbVie (ABBV) will present eight scientific posters through Allergan Aesthetics at AMWC Dubai, taking place October 21–23, 2026. The research covers HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic, following HArmonyCa's recent UAE launch.
In a subgroup analysis, all eight participants using GLP-1 weight-loss medications and treated with HArmonyCa showed visible midface improvement at three months; the findings are preliminary. Other data include improved patient-reported neck appearance and satisfaction after SKINVIVE treatment and satisfaction with repeated BOTOX Cosmetic treatment among Middle Eastern patients.
AbbVie (ABBV) entered a multi-year partnership with McLaren Racing to become an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team.
The partnership centers on AbbVie Race to Innovate, a campaign launching at the 2026 Formula 1 United States Grand Prix in Austin and expanding throughout the 2027 season. AbbVie will donate $10,000 for every 10 Constructors' Championship points earned by McLaren to global charities supporting people with immune-mediated diseases. Donations will support patient advocacy organizations providing education, resources and support, and will continue throughout the full 2027 season.
AbbVie (NYSE: ABBV) reported higher endoscopic remission rates with investigational ABBV-466 than either monotherapy in a Phase 2a Crohn's disease study. The ongoing, open-label TARGET-CD trial randomized 300 patients to ABBV-466, risankizumab or trosunilimab for 24 weeks. ABBV-466 combines the two therapies.
At Week 12, the primary endpoint, remission measured by bowel examination reached 30.2% with ABBV-466, versus 21.3% with risankizumab and 18.0% with trosunilimab. At Week 24, rates were 40.5%, 22.4% and 20.0%, respectively. Gene expression analyses showed intestinal tissue repair and barrier restoration at Week 12, followed by tissue remodeling and metabolic changes at Week 24. Serious adverse events occurred in 10.4% of ABBV-466 patients, versus 9.6% and 9.0% with the respective monotherapies. Results will be presented at the 2026 United European Gastroenterology Week Congress.
AbbVie (ABBV) will present new and updated solid tumor data at the ESMO Congress in Madrid on October 23–27, 2026. The program spans seven assets, including investigational treatments and approved medicines.
In Phase 1 colorectal cancer data, Temab-A plus bevacizumab showed median overall survival of 14.7 months versus 10.2 months with standard care. ABBV-706 produced a 56% response rate in a previously treated small cell lung cancer cohort. Additional findings cover Temab-A in lung cancer, ABBV-969 prostate cancer biomarkers and ABBV-1480 lung cancer treatment. Phase 3 studies of Temab-A, ABBV-706 and ABBV-1480 are ongoing. ABBV-1480 findings also identified severe treatment-related adverse events, including hypertension and proteinuria with monotherapy.